Projects
![]()
No projects found
Investors
New
DAO Treasuries
DATs
Lend / Borrow APRs
Chains
Categories
Spaces
eDMT Commons X BiomeAI // Edge City Collab
Recorded: Sept. 25, 2025 Duration: 0:56:21Space Recording
Short Summary
MicrobiomeDAO and SciDAO are launching Biome AI, a project focused on gut health and mental well-being, while also announcing significant funding for research on endogenous DMT. The collaboration highlights a trend towards decentralized science and community-driven research, with strong market engagement reflected in token staking.
Full Transcription
Thank you. Thank you. Hello, hello.
Hello.
How goes it?
It goes good.
I've been in a dark room for five days, and so I have tons of endogenous DMT.
So I'm ready to go on this.
Very nice.
How about you?
I've not been in a dark room, but I've been doing my breathing exercises.
Nice.
Yeah, staring at a screen as well.
So hopefully that's a little bit.
I don't know if that's going to help.
Yeah.
So I opened up microbiome DAO and...
microbiome.dow and
biome.ai.
Invite microbiome.dow to co-host.
I'll invite
to side out of co-host as well.
Okay.
Okay, I'm on a co-host now.
Cool, cool. okay i'm on a co-host now cool cool yeah we'll let people filter in for another few minutes and then we can get started hey microbiome down can you guys hey yeah we're here how's it going
good how are you good everything's good on my side hi Hi, Katya. Hey.
It's Riley. How you doing?
I'm good. Good to hear from you.
Yeah, nice to hear from you, too.
Sounds like microbiome's really doing well.
Yes. We're excited with our launch of Biome AI,
and so much more is cooking under the hood. Nice. Excited to hear about that.
Hey guys, Jim Jim, Kehoe here from Biomai. Hey Kehoe. Hey Kehoe. Hey guys, how's it going?
How's it going?
Going quite well.
We're cruising.
We got a lot of happening.
Yeah.
Yeah.
Aqueous, I'm inviting you to speak as well because you'll be, I'll put the mic over to
you later on once we start talking about our collaboration down at Edge City.
Yeah, so, Micah, how are things going on your side?
Hey, yeah, pretty well.
I mean, we just launched Biom AI. I think it was a few days ago.
I think the market perception was pretty good.
The price is kind of stabilizing right now.
We've seen a big kind of jump today.
The community is holding strong.
There's been like around 1.5 million of buy me I staked so far.
So pretty good results.
A lot of people participated in the sale.
And yeah, we're super excited to actually have our product out right now.
Some of our community members are testing it on Discord.
And, yeah, super happy to be presenting the product in the next few days or so.
Very cool.
Very cool.
Okay, yeah, so it looks like we've got a good room going on. So I'm just going to get started. I would like to talk about EDMT for a little bit,
and then I'll pass it over to you again. We can dig into more details if you guys,
if there's anything you want to speak specifically on. But yeah, I'll get it started. So endogenous DMT refers to dimethyltryptamine,
which is a powerful psychedelic that as the psychedelic science has kind of come out of the
banned lists of topics that governments and other centralized institutions don't want to occur,
we've been starting to
collect more and more data that shows that this psychedelic is actually produced in the brains
of human beings and other animals as well. It's produced actually in a lot of living organisms.
Dimethyltryptamine is found even in as early animals as coral, which are kind of the most prototypical animal that exists.
And so evolutionarily, dimethyltryptamine is one of the molecules that has been around for a while.
Now, the significance of endogenous DMT is, I think, vastly underappreciated. And it's part
of the reason that not only did we want to pursue this as a research topic under SIDL, but expand the intellectual property token to not represent
one individual research project, but an entire field of research. Because we really think that
EDMT will be a field of research, just like serotonin is a field of research or dopamine
is a field of research. Dimethyltryptamine, a recent paper, it was published just this year,
came out and said, hey, look, guys, dimethyltryptamine is produced in the brain. It's
stored in neurons. It's released upon some other biochemical processes. It interacts with other
receptors on other neurons. There's no reason that this shouldn't be considered a neurotransmitter.
Now, when serotonin was first discovered by scientists, it also was considered unimportant. And then only once science was actually funded and scientists
started looking into it and seeing how many processes serotonin was involved in, emotion,
mood regulation, social behavior, general health, it's released by the gut microbiome, it's released
by the brain, it's released by peripheral cells. Only then did we realize like, oh, serotonin is actually one of the most important molecules
in the body. We think the same thing for DMT. And we think the only reason that we don't know is
because DMT, we don't know this already is because DMT research, just like all psychedelic research
has been suppressed over the past few years. So this intellectual property token, we really feel is decentralized
science's serotonin moment, our moment to really introduce a molecule that is produced in our brain
that is involved in lots of things. We know that it's an agonist at the serotonin receptors,
and we also know that it's an agonist at sigma-1 receptors, also a very underexplored receptor that's involved in lots of different processes.
It has a really insanely cool mechanism of action.
There's actually two sigma receptors, sigma-1 and 2.
DMT seems to be an agonist for sigma-1, which suggests that it has some sort of regulatory power over these receptors interact in a way so it has regulatory
power over the whole entire sigma system. The commons IPT is a new concept that CIDAL has
developed as I mentioned earlier to represent in a field of research rather than an individual
project. We are looking to stack multiple lines of research under this intellectual property token
using the
trading fees and using their monies that we raised from this initial sale we've already raised a
significant amount of money we're going to be putting out a funding call soon we have a few
scientists who are already coming to side out and saying hey how can i get funding for my research
i want to look at edmt release upon breath work i want to look at edmt release upon breathwork. I want to look at EDMT release upon freediving. I want to look at
EDMT release in darkness retreats. And so there's a variety of different pathways that one could
explore and we'd like to explore about how we can regulate endogenous EMT release pharmacologically
and non-pharmacologically. But also we want to know where is it being produced? What is it doing
in the brain? What does it regulate? What are these other important processes that it regulates?
So yeah, that's the gist of the science. It's still, you know, it's been less than a week since
this token was launched, since the token went liquid. We're still collecting fees. We're really looking
forward to empowering token holders to vote and have a say in the direction of endogenous DMT
research. We're working on a media campaign into both the crypto spheres, the psychedelic sphere,
and then ultimately the mainstream sphere, introducing this concept, introducing our plans, introducing this community-backed, novel approach to doing science to the world.
And we think we're at the very first stages of it.
We're super stoked.
Another thing that we want to do eventually is enact some citizen science studies.
And I'll talk more about that once we go through some of the other things that we're
going to talk about on this call.
Super stoked to hear about Biome AI, Micome DAO's plans. That project is one of the
most exciting projects that's coming out. It's a super honor for us to be launched alongside and
to sort of develop this relationship as we go. And I'm so stoked to announce later in the call,
the collaboration that we're going to be working on down at Edge City next month.
So I'll hand the mic over to MicrobiomeDow to chat more about their project.
And then we can move on to this collaboration.
Yeah, thanks so much for this introduction.
Yeah, I just want to say that there's definitely a big overlap here. The
microbiome directly influences the neurotransmitters, as you said, like serotonin, dopamine, and GABA.
And yeah, psychedelics like DMT act on those serotonin receptors. So that means that gut
composition could modulate how someone experiences those states.
And on the other side, psychedelics might also shift gut brain signaling.
So pretty cool what we're trying to build together
and really excited for the collaboration that we're going to discuss
in the coming minutes with HCT Patagonia.
And I want to hand it over to BiomAI account and Kiko behind it
to tell us a bit more about our plans.
Awesome. Yeah. Thanks, guys.
So, yeah, like before we get into the study,
and I just want to give a big appreciation to SciDAO.
When we started MicrobiomeDAO, let's say nine months back,
SciDAO was one of the biggest inspirations for us
in the community science side of things, right?
Even though the first experiment that we funded
was a citizen science experiment
in one of the pop-up villages in India,
we tried to basically you know, like
basically worked with 45 participants and tried to understand the gut modulation based on a specific
diet. And that was quite interesting. But I was super happy when BioMai got, you know, like
listed along with EDMT for the ignition sale. It was a coincidence.
Like we didn't know that before,
but I was super happy that both of our projects
having that the sort of connection that we built over time
and going live at the same moment was purely coincidental.
I really loved that.
And a bit about BioMai and how this all connects
and how it connects to citizen science.
We built BioMai to be that, you know, a health agent somewhere within the spectrum of health apps on the one side and, you know, like modern LLMs like ChatGPT on the other side.
So BioMai could be placed somewhere in between it has elements of
these personalization from the health apps but it definitely is not a health app it's an it's an
agent where the dynamics is more fluidic here you you can imagine of having a blank canvas and
you can feed in any sort of information to buy me from microbiome report
your diet your sleep your you know like exercise routine you can dump any sort of information so
we are building this to be purely multi-model and one more interesting part is we are also trying to
And one more interesting part is we are also trying to, you know, reach to that space of mental health tracking because I had a startup before where we tried to capture this.
It failed because of the fact that mood is a very subjective thing.
And most of the apps or like or any questioners try to capture it in a very um you know objective way but
it is a subjective thing it changes every time based on whom you meet and what you eat and how
the weather is and all of that so what you can do with biomei is uh is a simple solution here
is the angle of self-reflection so you can record your voice today for two minutes just talking
about how you feel what how was your day and stuff like that and the voice gets stored and you can
come back again after a week and then you get to replay it and listen to yourself and decide whether
you feel better or you feel worse right just from your voice from your own words
right instead of us telling you hey look your biomarkers are shooting up you have high serotonin
you might be feeling happy right but this is not the case right like it's a very subjective thing
so we are trying to capture these things more you know with the with the nuance. And that's what bio-me-i is like,
super interesting in a way that it connects all of these external functional manifestations like
mood, energy, focus, our behavior, and all of that back to a physical phenomenon that's that's the gut microbiome right so as
Tyler was saying right like gut microbiome is heavily involved in
development of a bunch of these neurotransmitters who knows it might
have it might have some influence over endogenous DMTs and endogenous
cannabinoids receptors and all of that, probably I think we need more opportunity
and places to explore these questions.
And that's where the interesting part
of N of 10 trials come in.
And that directly links to this particular topic
of interest that we are discussing here.
Because the idea for the
zen often trial is you can align people with interested you know like interests or people
who want to like bust scientific myths as well right or like simple questions does coconut does
eating coconut oil really helps in uh you know cognitive performance because it's just like
a bunch of myths going around you can validate these hypotheses at scale you know you can combine
you can come together as 10 people together and you can just follow a protocol for 10 days
and out of that what we would derive is a know, somewhere transitioning between open hypothesis to a tested hypothesis,
a user-driven hypothesis. And the beauty of it is, imagine if we run like hundreds and
thousands of ENOFTEN trials parallelly, the amount of knowledge that the agent gets, that
too from participatory science and community-driven knowledge graphs.
So these are going to be the other end of the scientific knowledge spectrum.
On the other side, you have more sort of analytical, rigorous scientific literature coming out of academia.
And on the other side, you could have something that is purely developed and created,
and the knowledge is emulating from the uh the users
from the personal level so then once you get the chance to superimpose these two things
the personal knowledge graph and the scientific knowledge graph then is what i would say
practical science right things that are not just for the books but also for practical use cases
but also for practical use cases.
And to validate these, you know,
hypotheses or ideas at scale,
we need tools and we need infrastructure.
And we believe that BioMai is one of those infrastructures, right?
Which is going to help us build these, you know,
knowledge base, a collective knowledge base.
Yeah, I learned it there yeah
that's that's really that's really amazing i have a quick question and it comes from my background
studying honeybees for my phd one of the projects that i worked on was the impact of butyrate which
is a excreted by the gut microbiome of honeybees released into the bloodstream and then as a
short-chain fatty acid kind of permeates into the brain and the hypothesis I was looking at was one does it cross the blood
brain barrier but the larger question was if this this molecule produced by the gut microbiome was
actually affecting honeybee behavior and honeybees are an insane model for behavior. They live in a society that kind of is like a naturally selected DAO.
And so one of the things I was looking at was if, yeah, the gut microbiome impacts their behavior.
And this is also related to a broader question of whether the human gut microbiome might also impact our food-seeking behavior,
what types of food that we eat, but also our experience in experiencing that food so i'm wondering do you have any um anything to comment on that topic in general about the
effect of gut microbiome on behavior but also how an animal experiences the world
i think definitely there is a connection uh basically as a human being or any living organism we are kind of shaped by our
environment right why a certain ethnic group or a certain demographics of people behave in a certain
way or follow a certain diet is because of the place they live in and the genetics and the
ecosystem that really kind of shaped them so with this this thing, you can scale this up
to different populations as well.
For example, there was a recent study
that looked into the gut microbiome
of Honduran village population.
They found out 200 new species.
And imagine like, we haven't like really even scratched
the surface on how a global microbiome
looks.
We just like just the fact that 71% of the data that we have in the global database of
gut microbiome, human gut microbiome comes from Western population, primarily from America,
Canada, and Europe.
So then you have like more distribution
that needs to be done.
So you need to build tools and accessible solutions
that can help us map the global population.
Then probably this will help us connect
why a certain diet is quite functional
in a certain population, but doesn't behave the same way
in the other population, right?
And you can tie it back to the behavior.
This is definitely something that, you know, will be explored in future.
And I think tools like what we are building, be it community science, citizen science,
open science, or like AI agents, health agents, research agents, these are going to just speed up the process. We're just going to, you know, shift gears here and the speed of in which we understand
this is going to get accelerated so fast. Yeah. Yeah. Yeah. I think that and one of the things
I love most about what you guys are doing is that there's there's an intellectual curiosity about
exploring the gut microbiome and exploring the
species of the gut microbiome, just like we're still finding new species in the Amazon rainforest,
which some might say is the gut microbiome of the earth. When we are thinking about things
from a scientist's perspective, and we're just interested in answering a question,
we're often not thinking about, okay, how is this going to apply to broader
society besides just learning something new about ourselves and the world? But what you guys are
doing, or you're really making this connection between, okay, what is already inside us that we
can sort of activate and understand and adjust our behaviors and the products we're producing in
order to make targeted therapeutic recommendations to people.
And that therapeutic, because they're specific, doesn't mean you have a limited market.
You have an expanded market because you know the diversity and you know how to tease apart what products are going to be useful for certain groups of people, which I think is very,
very cool.
We're super excited.
This partnership between CIDAO and MicrobiomeDAO
and our project co-launching is a synchronicity,
but also this idea of looking inside
what is already inside us that we can activate
in order to make us healthier and happier human beings.
With that though, I to segue into the collaboration that
we're forming down at Edge City in Patagonia. I want to hand the mic over to Andrew to speak
on this and really help us tie together these two different forays into science into this
one project. Hello, hello, GM GMs, everybody on the call here. I'm very, very excited to be representing SciDao and MicrobiomeDao down at Edge City
for this collaborative study.
To give you guys a little bit of a background and kind of ties in to what was just discussed,
right, this environment that is impacting our subjective experience as people, as animals.
We, this is actually, you know, for those familiar, this actually, this concept kind of came from a
BR, AI post from back in August, talking about how, you know, we know the digestive system
plays an important role in drug reaction,
but going a step further, it's this broad relationship between meal composition,
what you eat, and drug metabolism, which is this topic of ongoing research. And the BR post
was focusing really on psilocybin, pssilocybin being the active component of magic mushrooms,
which is metabolized into psilocin in the stomach and small intestines.
And for those who are familiar with any mushroom Reddit thread
or Erowid posts dating back pre-Web 3,
you'll hear anecdotally that food might delay absorption and reduce
peak levels of psilocybin experiences, but we don't really have much characterizing of these
effects. So it raises the questions, you know, does meal prep, does what you eat, does your stomach
acidity, for instance instance influence the journey that these
compounds take for through our minds so that brings us to edge city where we have this
cohort of individuals at the edge of tech science web 3 research uh so on and so forth that are you
know kind of a biohacker mindsets we're going to have them in one place in San Martin de los Andes in Argentina. One baseline gut microbiome test when people arrive at Edge City. One 10 to 14 days later after recording their dietary intervention.
You know, people are coming from all around the world to one place in Argentina.
So different, expectantly, you'll have people eating different things during the time.
We'll be using Biome AI to collect that data.
And then a microbiome test after that dietary intervention, and then post-psychedelic experience. of a specific plant medicine or psychedelic substance,
mostly commenting on onset, intensity, duration,
and recovery.
And this will be the first of hopefully,
you know, a series of investigations of this type
into how the gut microbiome
can affect psychedelic experience.
Very cool. Very cool. I think that that sounds good. Can you share more about Edge City itself
and the unique environment that this provides for the study as well as what other sorts of things we want to do
down there? Yes, yes, absolutely. So yeah, like I said, these are people kind of at the edge of
their fields, hence the name, and you know, a lot of biohackers, a lot of longevity folks there.
And so, you know, these specific people who are, you know, more crypto native than the average Joe, we're going to be deploying a token for data model, leveraging some of what CyDAO has been putting together, as well as the biome AI that microbiome DAO has recently launched.
that MicrobiomeDAO has recently launched.
And this study is taking place over three to four weeks.
But actually, the third week of Edge City,
we are going to be implementing a full-blown psychedelic week at Edge City.
And this is in line with the global psychedelic week
that is taking place in different
spots all around the world in collaboration with large psychedelic organizations. And throughout
that week, we're going to have programming that's going to be about endogenous DMT. We're doing a
talk on psychedelics in architecture and the golden ratio seen in nature and what humans build.
And that programming, I am very excited about. We're kicking it off with a Kene life immersive
event, bringing down the Shipibo representative that has collaborated a lot on some of CyDial's work to give a talk on Shafibo worldview,
as well as, you know, introduce people to his people's art and plant medicines.
Very cool. Very cool. Yeah, we've been working closely with microbiome
Dow to develop the protocol for this. I wonder if they have anything to comment
on the significance of this study and what if they have anything to comment on the significance
of this study and what it means for future studies down the road.
Yeah. This is one of the interesting studies that I have come across so far. The reason
being that I think Tyler, you kind of mentioned this when I was talking, any drug or any food that you consume ends up in your gut.
And the first set of entities to touch this is the gut microbiome along with your own cells.
So the gut microbiome is quite influential in metabolizing any of these substances,
be it diet, drugs, or supplements,
or whatever, right? So there must be a direct correlation between how your gut microbiome
looks and how the drug or the food that you take is consumed and metabolized, right? And
from this notion, you can drive and, you know, just take it to the next level regarding the psychoactive substances.
It kind of connects to two ways.
One, it gets metabolized in the gut, and the gut is heavily linked to the brain.
So probably there is a two-way communication happening from the brain to the gut and if you have gone through a psychedelic experience you might feel that you know butterfly stomach or like stomach churning for certain psychedelic
experiences I think this is because of that right like the the gut muscles are like super
interconnected through the brain and when this happens you automatically feel the response in your gut, like a gut feeling, right?
And along like tying it back to the EDMT, in future, at least like microbiome DA research the compatibility of any drug that's
getting released in respect to gut microbiome is it compatible to the gut microbiome but if you
happen to know what your gut microbiome looks like you might be able to optimize your dosage
right you don't have to take the same dosage as everyone so this is the next
level of personalization because gut microbiome is the key that helps you to
personalize along with genetics so I think in future this study could pave
way for you know dose optimized experience of not just psychedelics but
beyond that any drug or even diet. Probably eating a certain food
could make you feel a certain way. This could also be figured out. And for all of that, I think
this study would pave a basement, right? And the study is designed in a way that we filter out
noise because it's a controlled environment. That's the beauty of these pop-up cities.
You have a very controlled environment where people live together in the same place, breathing same kind of air, water, and they kind
of share the same environment, right? So the noise that appears in the data will be reduced
considerably, and so that we could see interesting data points and patterns emerging out of this.
and so that we could see interesting data points and patterns emerging out of this.
Yeah, right on. I want to tie it back to EDMT for a second because tryptophan is an essential
amino acid that is also one of these molecules that first interacts with the entities in the
gut microbiome and tryptophan is the first step or the necessary ingredient to create a variety of neurotransmitters, including
serotonin, but also including dimethyltryptamine or DMT, EDMT.
So I'm wondering if a potential trajectory of research for both organizations is to look
at how tryptophan moves to the gut microbiome, if tryptophan levels or the metabolism of tryptophan has
any relation to endogenous DMT production.
We're looking at various regulatory pathways first, but eventually we're going to start
looking at how can we sort of optimize our own physiology non-pharmacologically to empower ourselves to produce this DMT at levels that can provide some sort of mental subjective effect or therapeutic effect, etc.
combined with certain types of breath work or certain types of other hypoxic situations could stimulate DMT release, cause mystical experiences, maybe help people access what's already inside of ourselves.
The other thing that's, go ahead.
No, just the comment, I mean, it really really relates to bring the back full circle. Right. We're talking about consciousness being affected by environment, both outside, of course. Right. But but also what we put inside and that ecosystem that's developing within us in the microbiome.
contextualize this further, we're looking at this as a partnership in consciousness, right?
Microbiome, that which is inside, psychedelics, that which connects you with this greater thing,
right? This greater entity, this greater consciousness, and connecting those two
things through that which is ourselves. And so to contextualize this further, we're perform
doing this study in colab
consciousness residency d
And I think I see them on
if they want to pop up jus
bit about it. But for those
and interested, please, p
the consciousness residenc account, look into it and interested, please, please, please follow the Consciousness Residency at Edge City account.
Look into it and please come down and join. Yeah, I brought what I think is Madison up.
Madison, if you'd like to give a spiel, we'd love it. Yeah. Can you hear me? Yes, we can.
Okay, cool. Yeah. Really excited to be here. The here. I don't know if you guys are familiar with Edge, but basically it's this pop-up village concept with cities popping up all over the world to kind of reimagine a new way to live and work. this from like a science perspective is there's a really unique opportunity to do unique
experimentation that's not like not possible in like sterile labs or clinics or in academia
just because of the setup.
It's like kind of a co-living setup.
So there's like ultra frequent sampling opportunities and other aspects of it that make it just a really, really interesting breeding
ground and space to be doing psychedelic experiments in particular, especially just because it's kind
of on the edge and it's kind of an immersive field. So really, really excited to be doing
this partnership with PsyDOW. side out yeah I mean like in general consciousness
is I think really important and it's so so incredible to be kind of a part of this cutting
edge science too and yeah I envision this being a very long-term kind of structure and I think
this is like edge city and this like pop-up city kind of models a really
great place to just kind of push the science forward so I'm really excited about this and
honestly we could also open it open up the floor if anyone has any questions about I don't know if
we like have time for that but yeah yeah, I'm just really excited.
You can also DM me, you can DM me on this account and I can give you more information if you're
interested in joining us or just like following along. Thank you. Thanks, Madison. Yeah, happy to
open the floor if anyone has any questions or wants to make a comment.
I'll bring you up to speak if you just request.
We can also kind of like do it async if people want to just dm me i'm happy to answer any questions uh yeah yeah for sure
i think um riley behind the side on main account is a um a wealth of great questions
uh riley anything here speak to you specifically or anything you want to
kind of ask as a representative of the broader audience?
I want to hear about the scientists that
CIDAW and EDMT are collaborating with to try to puzzle out this
important mechanism about how DMT is created in the gut. Who are we working with, Tyler,
and what are they about? Yeah, so the first project that we funded under the EDMT Commons
is a project led by Dr. Andrew Gallimore and Dr. Chris McCurdy. Andrew Gallimore is the director
of Newnautics, which is a non-profit focus on funding research in really the cutting edge of the
consciousness space. And that space spans a variety of different subjects, including endogenous DMT,
extended state DMT, so extending the DMT experience, which is often very short,
to a longer point so that one could explore the DMT state rigorously and, you know, collect data while
they're in there. So to sort of map this other dimensional space that DMT launches one into,
when taken in the right way. Andrew Gallimore is quite a renowned scientist within the psychedelic
sphere for a variety of books he's written as well
as his phd research but he's written books on theories behind what dmt is what it means for
humanity what sort of the beings that one comes into contact with in the dmt space are and what
they might you know represent to us in our subconscious or what they might be in
some sort of other dimensional reality.
So the project that they're working on is looking at this underexplored class of peptides,
which were identified back in the 70s in a couple papers which were buried,
either due to the scientists losing interest or because of the world on drugs, who knows.
But in the course of researching for his latest book, Death by Astonishment,
Andrew found that there is this regulator of INMT.
INMT is the enzyme that converts tryptamine
to dimethyltryptamine.
And so if this peptide class can be identified,
it could potentially be switched off,
which would allow more INMT to exist
in these areas where DMT is synthesized,
resulting in the increased synthesis of DMT.
So we're looking at like,
there's the final step to produce DMT.
We're looking at a step in this biochemical pathway a few steps back,
inhibiting the thing that inhibits DMT synthesis.
The research project will first look for these peptides in rabbits to replicate the original paper.
When it identifies the peptides, the researchers will characterize them. They should be some sort
of amino acid chain peptide. Once it's classified, we can then start studying it regularly to see
what sorts of things can we do to turn it off. How can we turn off the thing that turns off DMT?
So that's the initial project. It should last about a year. It's already
the first milestone is expected to be reached this fall. So we're hoping in October or early
November, we have an update from the lab at University of Florida that says, look, we
found this peptide. Our next steps are to run it through these variety of other assays that will characterize it,
will confirm its activity in inhibiting INMT, and then we'll start looking at how we can regulate it.
So this is the first study. The other studies that are in our periphery that we expect to
answer our call for funding more proposals are from other psychedelic scientists
that are looking at endogenous DMT in various hypoxic states. So one of the most interesting
ones to me is this phenomenon where free divers, so people that are diving deep into the ocean
with no gear, have these sort of mystical experiences while they're down there.
You know, maybe one could assume that they are experiencing a sort of like intentional near death experience because they're just so far below any sort of environment that humans evolve within.
And so this disconnection maybe creates some sort of like otherworldly experience.
And so this disconnection maybe creates some sort of like otherworldly experience.
But this researcher understanding that, you know, phenomenon are caused by chemicals and being a psychedelic researcher who's renowned in researching 5-MeO-DMT, which is an analog of the DMT that we're talking about.
She recognized that maybe there's DMT being released.
She recognized that maybe there's DMT being released.
And if we can only study basically the molecules that they've excreted in their urine after diving,
could we understand if DMT is being released?
Because there are hallmark biometabolites that can be found after DMT has gone through the body.
gone through the body. So she is looking for funding for that study. We have another researcher
So she is looking for funding for that study.
in Germany who's looking at if breathwork and certain types of breathwork are releasing endogenous
DMT and is that the cause of the mystical experiences and really transpersonal experiences
people experience undergoing Wim Hof or holotropic breathwork. Another research project that's in a periphery is whether long-term exposure to darkness can
stimulate endogenous DMT. And so this is just evidence that there's a lot of different lines
into understanding this, and we don't know which one is going to turn out the protocol or the
pharmaceutical that's going to stimulate DMT synthesis and DMT synthesis in a amount that
will allow one to sort of enter the world that DMT can bring you into.
But we want to fund all of it.
You know, we're hoping that we can really coordinate all of these scientists under one
umbrella, but not just to fund it, but also to get them in the same room talking about
how they're running their studies.
What are they, what metabolites are they looking at?
If they can synchronize the endpoints that are looking at the statistical methods that
they're looking at the statistical rigor that they're looking at these metabolites in, we
can then group all of these projects under a larger meta-analysis with consistent data architecture
to draw these meta results and meta findings from across different studies and then the other you know third reason that we wanted to develop our this project this first project and this law these
other projects in this way is just to put out a beacon to other scientists and say, hey, look, there's a place for you to study this really bleeding edge area of psychedelic research.
There's a community behind it. There's an ecosystem that is interested in supporting it.
There are people around the world who want to know if this is something that they can access themselves.
And that's how we see the community as just the first organized group of
people that is creating a concerted effort to understand this new neurotransmitter and this new
molecule with so many mysteries behind it. So I hope that answers your initial question.
Yeah, it does. And I just want to say how when I first took DMT nearly 20 years ago, it was one of the
most amazing things that I had ever seen in my entire life.
It's up there with bioluminescence or watching a volcano explode.
I thought, what a strange and interesting and otherworldly thing.
And then later I learned this is inside me.
It's not something that's separate. And how amazing is that, that our body is involved in something that is among the most
beautiful, strange things in nature.
And why is that?
And can we learn more about that?
Because learning more about ourselves and the way we work is generally a good thing.
Long-term for health.
So again, there's a wonderful synchronicity with us and microbiome
getting in touch with what's inside us these things that can seem so strange like bacteria in
the gut why would we have bacteria in the gut well turns out it's incredibly important and we think
that's the same with tmt does anyone else have questions, thoughts?
We can bring you guys up to speak.
Bioprotocol, Molecule, Jesse, Brittany, Pumpsy.
Really nice to see all you guys.
Yeah, if not, I would love to hand the floor over back to MicrobiomeDAO. If there's any other projects or sorts of updates you guys have on the development of
the DAO, the larger infrastructure you're building, some of the other ideas that you
guys have just been floating around in the DMs and in the back rooms, basically, of a
DAO, we'd love to hear about any of them or maybe teas or whatever you can share.
Because, yeah, we are always looking for more surface area to interact with you guys.
Yeah, definitely I can chime in there.
So when we realized, right, microbiome reports are, like, microbiome tests are your key to look into what your gut microbiome holds.
We started looking at the landscape.
How many people realistically has the capacity to or like the can afford to take a microbiome test?
Right.
It's quite low because these tests are like priced at somewhere around 50 to 250 dollars depending
on the depth and the the analysis that you want to do and so then we realized what could
be the most frictionless step that we can enable for our community and like the general
audience to get some awareness towards gut health. And that's where we stumbled upon poop monsters.
So this is called Poop AI.
This is Poop Observation and Optimization Protocol.
What it does is basically you can take a picture of your poop
and it analyzes what stool type it is.
and it analyzes what type of uh what stool type it is and it can look at the color the float
and other factors like mucus or blood whatever is there in that and you can also self-report
certain things on top of your poop data and eventually once we start collecting this data
for a longer time what happens is then you can build a connection between
your diet and your poop so what you eat and what comes out as a biological waste right and this
could be the the number one gut health indicator and if we notice anything that is drastic or
extreme we basically you know trigger to take a medical advice or even to get a
microbiome test.
So then we can then connect diet, poop, and the microbiome test.
So once we train the model with such a sophisticated data sets, probably in a few years, we'll
be able to at least partially eliminate microbiome tests. And just by looking at your poop images,
we'll be able to inform a basic level of a gut health index.
And that's what we are moving towards,
building that data set in a very fun way.
You basically get a monster
whenever you take a picture of your poop
and you can feed the monster
by feeding in your diet information and you can
grow these monsters to win a level like a golden level and once you get a golden level you can use
these monster to generate a free microbiome test kit so that's how it works something on the lines
of poop to earn model but most of it has a scientific basis and a gamified thing we are developing this
for you know the younger generation but also like everyone so that you know we we start to build this
data set right on from from now onwards yeah cool and i know that that's also how we're going to be collecting data down at Edge City. So
are you sort of, is the Edge City protocol and experiment sort of helpful in, you know,
preliminary information about how to, you know, motivate people, how to make sure that what we
have to do to motivate people to, you know, give their poop samples is this is that sorry is the protocol down in a city basically going to help you guys at all help develop a protocol for you have for the poop monsters.
have we could enable this api um we already have the app but we could enable this api within biome
ai so people can just you know capture their capture the images of their poop every day and
and here it's it's it's uh it's not gonna give like a super scientific explanation rather than
it's gonna look at your poop and say hey this is tool type 7 you might be uh diariating so probably you need to take
a certain kind of food that could that's helpful for you to you know come out of this so it's based
on medical uh evidences and and things it's it's not gonna prescribe anything drastic to you it's
just gonna give you advices like you know hey drink more water hey do this you know it just
gives you more information and
it's a way to log your health data like how you log your steps your sleep and this is also an
important uh biometric that you need to kind of document and uh yeah let's see like if if the
because there is a certain kind of there's a certain stigma attached to poop and
images in in some of the uh you know geographical uh areas like in demographics it's it's seen
different um so we need to see like how uh the participants feel about it if if they
they are willing to test it, we can definitely make it happen. Yeah.
are willing to test it uh we can definitely make it happen yeah
That's great. That's great. Well, we're nearing the end of our hour. I put out another,
I'll put out another call. If anyone does want to jump up and speak, ask a question,
leave a comment, we would appreciate it. If not, if I don't get one by the time I finish
what I'm saying here, I'll close the space,
but just wanna say thank you to everyone for chiming in.
We're really excited about the collaboration between
SciDAO and MicrobiomeDAO,
but between EDMT Commons and BiomeAI
as these two ignition cell launches,
which I think we can all agree has been quite a success so far.
And we're really excited for what this model will bring us
and what sort of new insights into ourselves.
It'll bring MicrobiomeDAO or Aqueous wants to share any more
or just have any sign-off message.
I'll let you guys chime in.
But otherwise, keep an eye out. We're going to have another space from the EDMT Commons account
sometime next week with the neonautics and researchers behind our first funded study.
And then we'll continue after that with the series on bringing in other DMT scientists. But
yeah, if anyone else wants to just give a last shout out, please.
Just a shout out, please, to stay up to date with our study.
And please, please give me a follow.
Please follow Sidal for sneak peeks of what's dropping at psychedelics week next month.
That is going to be coming over the next couple of weeks.
We're going to be teasing some of the programming that we have developed for
psychedelics week.
But thank you very much to the EDMT squad, PsyDow,
Biome AI squad and Microbiome Dow for, for, you know,
making this collaboration happen down at Edge City
and so excited to see what comes of it.
Yeah, likewise.
Thank you so much for hosting EDMT and excited for our collaboration.
Really important event here that's going to happen at Edge City at the Consciousness
Residency.
I think this is truly valuable as we bridge this personal transformation,
the collective one,
and really enabling the community science.
So we're really excited to continue working together
and stay tuned for updates from the BiomAI account
on the agent, on the terminal release,
and any news from microbiome dial account as well.
We're really happy building this together
and enabling community science at scale.
Yeah, thank you, guys.
Thanks for the opportunity to discuss our collaboration.
Happy to be here. Yeah. Thanks for the opportunity to discuss our collaboration.
Happy to be here.
Yeah.
Right on.
All right.
Well, thank you guys.
Follow along, and we'll chat soon.
Bye now.
Thank you, everybody.
Have a great day.
Have a good one.
Bye.
Bye. Bye.
